Introduction: The combination chemotherapy of docetaxel, cisplatin and 5-fluorouracil(5-FU) has shown better survival and response rate than 5-FU/Cisplatin, however the toxicity was substantial. The aim of this study is to determine the efficacy and toxicity of docetaxel, oxaliplatin and 5-FU(DOF) combination chemotherapy in patients with advanced gastric cancer. Methods: Seventeen patients with advanced gastric cancer were treated with the following regimen every 21days: docetaxel 60 mg/m2 IV on day1, oxaliplatin 100 mg/m2 IV on day1, and 5-FU 850 mg/m2 continuous infusion on days1-4. Results: Ten(58.8%) patients showed partial response, 5(29.4%) patients showed stable disease. The overall response rate was 58.8%(95% CI: 35.9-78.4%) and the disease control rate was 88.2%(95% CI: 64.4-97.9%). A total of 100 cycles of chemotherapy was administrated and the dose intensity was 92.4% in docetaxel, 90.9% in oxaliplatin, and 96.6% in 5-FU. The median progression free survival was 6.7months(95% CI, 6.2-7.2 months). Grade3/4 neutropenia and thrombocytopenia occurred in 28cycles(28%) and 1cycle(1%). Grade3 stomatitis, diarrhea and neutropathy occurred in 1cycle(1%), 4cycles(4%) and 5cycles(5%), respectively. Conclusions: The combination chemotherapy of docetaxel, oxaliplatin and 5-FU (DOF) is effective for the treatment of advanced gastric cancer and well tolerated. This result support the continuation of the phaseII trial until target recruitment(n=50).